Terapias dirigidas en combinación con hormonoterapia en cáncer de mama avanzado HER2- negativo - page 9

Rationale for PI3K inhibitors in HR+ Breast

Cancer

Fulvestrant

BYL719

BKM120

E2F

BCL2

Proliferation

Survival

Exemestane

ERBB3

IGF1R

S6K

mTOR

RAD001

pS167

GATA3

LEE011

CDK4

pRB

CCND1

PIK3CA

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4,5,6,7,8 10,11,12,13,14,15,16,17,18,19,...45